Answers are grounded in this paper and cite their sources.
The duration of diabetes may be an important, previously neglected factor in evaluating bleeding risk for patients with non-valvular atrial fibrillation on direct oral anticoagulants.
Atrial fibrillation and diabetes: time to reconsider duration of the disease to evaluate the bleeding risk? Impact of diabetes status in patients suffering of non-valvular atrial fibrillation requiring anticoagulation have been analysed previously and risk/benefit balance of NOACs have been confirmed in these patients. The implication of that pathology in the evaluation of the thrombotic risk is discussed but more importantly bleeding risk in this growing population is analysed, perhaps neglected until now.
No takes yet. Share an insight, caveat, or question.
Gach et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: